Xencor, Inc Deferred Tax Assets, Gross
Xencor, Inc (XNCR) had Deferred Tax Assets, Gross of $277.88 million as of 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsGross · last filed 2026-02-25
- 2025-12-31: Deferred Tax Assets, Gross $277.88M.
- 2024-12-31: Deferred Tax Assets, Gross $247.00M; Deferred Tax Assets, Gross as first filed $247.51M.
- 2023-12-31: Deferred Tax Assets, Gross $200.56M; Deferred Tax Assets, Gross as first filed $179.91M.
- 2022-12-31: Deferred Tax Assets, Gross $142.69M; Deferred Tax Assets, Gross as first filed $130.68M.
| Period end | Deferred Tax Assets, Gross | Deferred Tax Assets, Gross as first filed |
|---|---|---|
| 2025-12-31 | $277.88M 10-K · filed 2026-02-25 | |
| 2024-12-31 | $247.00M 10-K · filed 2026-02-25 | $247.51M 10-K · filed 2025-02-27 |
| 2023-12-31 | $200.56M 10-K · filed 2025-02-27 | $179.91M 10-K · filed 2024-02-29 |
| 2022-12-31 | $142.69M 10-K/A · filed 2025-02-24 | $130.68M 10-K · filed 2023-02-27 |
| 2021-12-31 | $104.78M 10-K · filed 2023-02-27 | |
| 2020-12-31 | $115.10M 10-K · filed 2022-02-24 | $114.95M 10-K · filed 2021-02-24 |
| 2019-12-31 | $81.71M 10-K · filed 2021-02-24 | |
| 2018-12-31 | $85.83M 10-K · filed 2020-02-25 | |
| 2017-12-31 | $60.71M 10-K · filed 2019-02-26 | $70.33M 10-K · filed 2018-02-28 |
| 2016-12-31 | $73.71M 10-K · filed 2018-02-28 | |
| 2015-12-31 | $79.93M 10-K · filed 2017-03-01 | |
| 2014-12-31 | $63.19M 10-K · filed 2016-03-08 | |
| 2013-12-31 | $87.50M 10-K · filed 2015-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |